Related content

Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review

By  

Drug Delivery Letters, Vol. 4, Iss. 3, 2014-12 ,pp. : 193-207

Bentham Science Publishers

Access to resources Recommend Favorite

Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials

By Máiz Luis   Girón Rosa M   Olveira Casilda   Quintana Esther   Lamas Adelaida   Pastor Dolores   Cantón Rafael   Mensa Josep  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1135-1149

Informa Healthcare

Access to resources Recommend Favorite

Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies

By Hassett Daniel J   Korfhagen Thomas R   Irvin Randall T   Schurr Michael J   Sauer Karin   Lau Gee W   Sutton Mark D   Yu Hongwei   Hoiby Niels  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 2, 2010-02 ,pp. : 117-130

Informa Healthcare

Access to resources Recommend Favorite

Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients

By Ehsan Zarmina   Wetzel Jacqueline Denise   Clancy John P  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 5, 2014-05 ,pp. : 743-749

Informa Healthcare

Access to resources Recommend Favorite

Inhaled Tobramycin (TOBI®): A Review of its Use in the Management of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis

By Cheer S.M.   Waugh J.   Noble S.  

Drugs, Vol. 63, Iss. 22, 2003-01 ,pp. : 2501-2520

Adis International

Access to resources Recommend Favorite